Company Filing History:
2 out of 444 
2 out of 8,396 
2 out of 2,896 
Years Active: 2024
Title: The Innovative Contributions of Mario Suva
Introduction
Mario Suva is a prominent inventor based in Boston, MA (US), known for his significant contributions to the field of cancer research. With a total of 2 patents, he has focused on developing methods and compositions that target specific oncogenic programs, particularly in gliomas.
Latest Patents
Suva's latest patents include groundbreaking work on "Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas." This patent addresses the treatment of diffuse gliomas with histone H3 lysine27-to-methionine mutations (H3K27M-gliomas). The disclosed methods involve gene signatures specific for tumor cell types and compositions aimed at treating H3K27M gliomas, with a particular focus on targeting PRC1 in treatment regimens.
Another notable patent is "Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway." This invention provides methods for treating cancer by blocking the interaction of KLRB1 with its ligand, which is crucial in the context of glioblastoma multiforme (GBM). The patent highlights the role of KLRB1, a C-type lectin protein, in inhibiting the cytotoxic function of NK cells and cytokine secretion, thus offering a novel approach to cancer treatment.
Career Highlights
Throughout his career, Mario Suva has worked with esteemed institutions such as the Broad Institute, Inc. and the Massachusetts Institute of Technology. His research has significantly advanced the understanding of cancer biology and therapeutic strategies.
Collaborations
Suva has collaborated with notable scientists in the field, including Aviv Regev and Itay Tirosh. These collaborations have further enriched his research and contributed to the development of innovative cancer treatments.
Conclusion
Mario Suva's work exemplifies the intersection of innovation and medical research, particularly in the fight against cancer. His patents and collaborations reflect a commitment to advancing therapeutic strategies for challenging oncogenic conditions.